GLPG - ガラパゴス （Galapagos NV）GLPGのニュース
Galapagos to transfer drug discovery and research activities in France to NovAliX 2023/03/30 22:39:41 Seeking Alpha
Galapagos NV (GLPG) on Thursday said it would transfer its drug discovery and research activities in Romainville, France to contract research organization NovAliX. Read more here.
Galapagos NV: Galapagos and NovAliX enter into an integrated drug discovery collaboration 2023/03/30 20:34:00 Finanz Nachrichten
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (CRO) based in Strasbourg, FranceNovAliX to a…
Galapagos and NovAliX enter into an integrated drug discovery collaboration 2023/03/30 20:30:00 Wallstreet:Online
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (CRO) based in Strasbourg, France NovAliX to assume Galapagos’ research capabilities, and Galapagos retains flexibility to access necessary expertise and resources through a five year-collaboration agreement Transaction in the context of
Galapagos NV: Galapagos publishes 2022 annual report and announces Annual Shareholders'' Meeting 2023/03/23 20:10:00 Finanz Nachrichten
Publication of annual report for financial year 2022Annual Shareholders'' Meeting proposed resolutions include re-appointment of Board members and appointment of new statutory auditor Mechelen, Belg…
Galapagos NV: Galapagos increases share capital through subscription right exercises 2023/03/20 20:10:00 Finanz Nachrichten
Mechelen, Belgium; 20 March 2023, 21.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos i…
Jefferies Upgrades Galapagos NV to Hold 2023/01/23 07:00:02 Investing.com
https://www.investing.com/news/pro/jefferies-upgrades-galapagos-nv-to-hold-432SI-2985479
Galapagos Stock: Setting Up For Transformation (NASDAQ:GLPG) 2022/12/31 05:54:12 Seeking Alpha
Galapagos is setting up to transform its business after a slew of failures. Read more to see why I think GLPG will be successful in its transformation plans.
On A Mission As Top European Player, Galapagos Looks For Acquisition Targets 2022/12/20 13:17:49 Benzinga
Galapagos NV (NASDAQ: GLPG ) is reportedly looking for M&A deals with companies with products still in the preclinical or early stage of development. The former chief scientific officer of Johnson & Johnson (NYSE: JNJ ) took the reins at the struggling Belgian biotech this year. Paul Stoffels is on a "mission," Financial Times reported , to reinstate Galapagos as a top European biotech … Full story available on Benzinga.com
Belgian biotech company Galapagos on the hunt for deals 2022/12/20 05:00:42 Financial Times
News, analysis and comment from the Financial Times, the worldʼs leading global business publication
Galapagos NV: Galapagos announces CHMP adoption of PRAC''s recommendation for Jyseleca following extensive safety review of all JAK inhibitors 2022/11/11 12:17:00 Finanz Nachrichten
Supportive outcome for Jyseleca as treatment option with a positive benefit/risk profile after review of safety data of all JAK inhibitors approved in Europe for treatment of inflammatory condition…
Galapagos NV PT Raised to $63 at Morgan Stanley 2022/10/13 12:47:13 Investing.com
https://www.investing.com/news/pro/galapagos-nv-pt-raised-to-63-at-morgan-stanley-432SI-2911623
Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product (NASDAQ:GLPG) 2022/10/10 17:16:22 Seeking Alpha
Galapagos has a new CEO since April 2022. The new strategy is taking shape with some research programs scrapped and small assets acquired. Read more here.
Galapagos NV: Galapagos receives positive CHMP opinion for Jyseleca European label update based on testicular function safety data from MANTA/RAy studies 2022/10/03 20:05:00 Finanz Nachrichten
Type II variation1 regulatory application to amend the European label of Jyseleca (filgotinib) based on data from MANTA and MANTA-RAy studies in patients with inflammatory bowel disease (IBD) and r…
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies 2022/10/03 20:01:00 GlobeNewswire
Type II variation 1 regulatory application to amend the European label of Jyseleca ® (filgotinib) based on data from MANTA and MANTA-RAy studies in patients with inflammatory bowel disease (IBD) and rheumatic conditions (RC) respectively
Galapagos receives positive CHMP opinion for Jyseleca European label update based on testicular function safety data from MANTA/RAy studies 2022/10/03 20:01:00 Wallstreet:Online
Type II variation1 regulatory application to amend the European label of Jyseleca (filgotinib) based on data from MANTA and MANTA-RAy studies in patients with inflammatory bowel disease (IBD) and rheumatic conditions (RC) respectively Mechelen, Belgium; 3 October 2022, 22.01 CET, regulated information; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal